Globe Newswire (Tue, 31-Mar 7:00 AM ET)
Biomea Fusion Projects Multiple Clinical Data Readouts in 2026 as R&D Spending Drops 47%
Market Chameleon (Wed, 25-Mar 7:58 AM ET)
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Globe Newswire (Tue, 24-Mar 4:05 PM ET)
Globe Newswire (Sat, 14-Mar 4:30 AM ET)
Biomea Fusion to Participate at Upcoming Investor Conferences
Globe Newswire (Thu, 19-Feb 7:00 AM ET)
Biomea Fusion Sets Sights on Key Diabetes and Obesity Milestones in 2026 Clinical Pipeline
Market Chameleon (Mon, 12-Jan 6:52 AM ET)
Market Chameleon (Wed, 10-Dec 6:45 AM ET)
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Biomea Fusion trades on the NASDAQ stock market under the symbol BMEA.
As of April 15, 2026, BMEA stock price declined to $1.94 with 167,225 million shares trading.
BMEA has a beta of 1.73, meaning it tends to be more sensitive to market movements. BMEA has a correlation of 0.06 to the broad based SPY ETF.
BMEA has a market cap of $140.26 million. This is considered a Micro Cap stock.
In the last 3 years, BMEA traded as high as $43.69 and as low as $.87.
The top ETF exchange traded funds that BMEA belongs to (by Net Assets): VTI, VXF, IWC.
BMEA has underperformed the market in the last year with a return of +19.8%, while SPY returned +30.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BMEA shares. However, BMEA has outperformed the market in the last 3 month and 2 week periods, returning +19.8% and +26.8%, while SPY returned +1.0% and +6.9%, respectively. This indicates BMEA has been having a stronger performance recently.
BMEA support price is $1.81 and resistance is $2.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMEA shares will trade within this expected range on the day.